A carregar...
Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD
BACKGROUND: When faced with uncertainties about the effects of medical interventions regulatory agencies, guideline developers, clinicians, and researchers commonly ask for more research, and in particular for more randomized trials. The conduct of additional randomized trials is, however, sometimes...
Na minha lista:
| Publicado no: | BMC Med |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4490602/ https://ncbi.nlm.nih.gov/pubmed/26137986 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-015-0398-0 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|